Business Context and Reporting Period
Pacific Biosciences of California, Inc. (PacBio) is a life science technology company developing advanced sequencing solutions, including HiFi long-read and Sequencing by Binding (SBB) short-read technologies. This Form 10-Q covers the quarterly period ended September 30, 2024. The company is currently focused on commercializing its Revio and Onso platforms and preparing for the launch of the Vega benchtop system in early 2025.
Key Financial Metrics
| Metric | Q3 2024 | Q3 2023 | 9 Months 2024 | 9 Months 2023 |
|---|---|---|---|---|
| Total Revenue | $39.97 million | $55.69 million | $114.79 million | $142.16 million |
| Gross Profit | $10.00 million | $17.90 million | $27.22 million | $43.21 million |
| Gross Margin | 25% | 32% | 24% | 30% |
| Operating Loss | $(64.08) million | $(82.49) million | $(321.29) million | $(246.92) million |
| Net Loss | $(60.73) million | $(66.87) million | $(312.22) million | $(224.72) million |
| Cash & Investments | $471.15 million | $631.42 million | As of Sept 30, 2024 | |
| Convertible Debt (Principal) | $893.14 million (Net) | $892.24 million (Net) | As of Sept 30, 2024 |
Note: Debt figures represent the net carrying amount of convertible senior notes. Principal amounts outstanding were approximately $441 million (2030 Notes) and $459 million (2028 Notes) prior to a subsequent exchange agreement.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 28% in Q3 and 19% for the nine months ended September 30, 2024, compared to the prior year. This was primarily driven by a 52% drop in instrument revenue (fewer Revio unit sales) partially offset by a 10% increase in consumable revenue.
- Goodwill Impairment: The company recorded a non-cash goodwill impairment charge of $93.2 million in the second quarter of 2024 due to a decline in stock price and market capitalization, significantly impacting the nine-month operating loss.
- Restructuring Costs: The company incurred approximately $24.7 million in cumulative restructuring charges for the nine months ended September 30, 2024, related to workforce reductions, the closure of the San Diego office, and excess inventory provisions.
- Amortization Increase: Amortization of acquired intangible assets increased significantly ($6.6 million for the nine months) due to the Apton acquisition assets.
- Cash Position: Cash, cash equivalents, and investments decreased by approximately 25% year-over-year to $471.1 million, reflecting operating cash outflows of $175.4 million for the nine-month period.
Guidance, Outlook, and Risks
- Product Outlook: PacBio announced the Vega benchtop long-read sequencing system in November 2024, with orders taken in Q4 2024 and shipments expected in Q1 2025. Management expects Vega to be accretive to gross margins as it scales.
- Expense Reduction: The company is implementing initiatives to reduce annualized run-rate operating expenses by the end of 2024. Approximately $2.1 million in additional restructuring costs are expected through 2025.
- Debt Restructuring (Subsequent Event): On November 7, 2024, PacBio agreed to exchange the remaining ~$459 million of 2028 Notes for $200 million of new 2029 Notes, 20.45 million shares of common stock, and $50 million in cash. This is expected to close in late November 2024.
- Key Risks:
- Sales Cycles: Median sales cycles for Revio instruments remain longer than expected due to customer funding uncertainty and procurement delays.
- Profitability: The company does not expect to be profitable in 2024 and anticipates continued operating losses.
- Legal Proceedings: Ongoing patent infringement litigation with Personal Genomics of Taiwan (PGI) and Take2 Technologies/CUHK, with trial dates set as late as 2026.
- Geopolitical: Risks related to U.S.-China trade tensions and supply chain dependencies, particularly for components manufactured in China or Taiwan.
Investor Verification Checklist
- Debt Exchange Terms: Verify the final terms and dilution impact of the November 2024 exchange of 2028 Notes for 2029 Notes and equity.
- Goodwill Valuation: Assess the assumptions used in the goodwill impairment test and the potential for future impairments given stock price volatility.
- Revio Adoption Rate: Monitor the installed base growth and subsequent consumable revenue ramp-up to validate the transition from instrument to recurring revenue.
- Restructuring Execution: Track the realization of cost savings from the San Diego office closure and workforce reductions against the projected $2.1 million remaining costs.
- Liquidity Runway: Confirm that the remaining $471 million in cash and investments is sufficient to fund operations through the Vega launch and beyond, considering the $50 million cash outflow required for the debt exchange.